AV Therapeutics, DavosPharma Enter GMP Pact

AV Therapeutics has entered into an agreement with DavosPharma to provide GMP synthesis of its lead drug candidate Capridine. DavosPharma expects to complete the manufacture of the drug in 2Q14.
 
AV Therapeutics is in the process of preparing its IND application for the FDA, and hopes to begin its Phase I trial in 4Q14. Preclinical studies have shown Capridine has specific activity towards both hormone dependent and independent prostate cancer with minimal bone marrow toxicity.
 
Dr. Abe Mittelman, M.D., chief executive officer of AV Therapeutics, said, “I am pleased at our progress in moving forward with the manufacturing of Capridine. This is an important step as we prepare for our human clinical trials.”